Genedata Profiler Moves to High-Performance Clouds
Innovative enterprise platform for clinical cross-omics now also accessible via high-performance cloud computing services Microsoft Azure and Amazon Web Services
December 20, 2017
Genedata, a leading provider of advanced software solutions for biopharmaceutical research and development (R&D), today announced that Genedata Profiler™, its leading enterprise software platform for omics-based profiling of patients in translational and clinical research, can now also be deployed in cloud environments such as Microsoft Azure (MS Azure) and Amazon Web Services (AWS), additional to on-premises and private cloud environments. This addresses the rapidly increasing demand from translational and clinical research groups that lack in-house IT support and need fast access to a fully integrated data platform.
Genedata Profiler enables the processing, management and analysis of massive amounts of globally distributed raw genomic, transcriptomic, metabolomic and proteomic data from technologies such as next-generation sequencing, microarray and real time-PCR, in conjunction with clinical and other phenotypic data. The enterprise architecture of Genedata Profiler facilitates access to the data and analysis algorithms by team members located at different sites, thus driving harmonization of processes across an organization. Deployment in high-performance clouds allows Genedata Profiler to offer a highly flexible and elastic solution to its clients, who enjoy the “compute on demand” benefit of booking more computing power instantaneously to deal with rapidly expanding data processing demands.
Genedata has now successfully deployed Genedata Profiler in advanced cloud settings for several biopharma clients headquartered in Europe and the USA, with globally distributed research teams. With servers, storage, networking, and virtualization managed by the cloud hosts, and Genedata taking care of the application software, the research organization is free to focus on its core competencies: processing and analyzing its research trial data through workflows in Genedata Profiler to identify biomarkers crucial for the precise targeting of its therapy under investigation.
"With its highly scalable software architecture, Genedata has been at the forefront of the management, processing, and analysis of big scientific data sets for many years," commented Dr Othmar Pfannes, CEO of Genedata. "Now with Genedata Profiler accessible on high-performance cloud platforms like AWS and MS Azure as well as on-premises, we offer even more flexibility and convenience to our clients working on tasks like biomarker discovery for clinical development in therapeutic areas such as immuno-oncology, neurology and cardiovascular disease."
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, the UK, Japan, and the US.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.